围术期应用帕瑞昔布对胶质瘤患者术后生存期的影响

Effect of perioperative use of parecoxib on postoperative survival time on patients with glioma

中文关键词: 围术期  帕瑞昔布  胶质瘤  无进展生存期  总生存期

英文关键词: Perioperative  Parecoxib  Glioma  Progression-free survival  Overall survival

中文摘要:

      
目的：探讨围术期应用帕瑞昔布对胶质瘤患者术后生存期的影响。
方法：回顾性分析2019年1月至2023年5月全身麻醉下接受胶质瘤手术治疗的患者资料。根据围术期是否应用帕瑞昔布将患者分为两组：帕瑞昔布组（P组）和对照组（C组）。收集患者一般资料、围术期资料以及术后生存资料，包括无进展生存期（PFS）和总生存期（OS），随访截止日期为2024年5月1日。对患者基线数据进行倾向性评分1∶1配对。采用Kaplan-Meier法比较两组生存时间。采用多因素Cox比例风险模型筛选影响患者生存期的因素。
结果：本研究共纳入患者388例，其中P组203例，C组185例，倾向性评分配对后每组117例。P组中位PFS为14个月（95%CI 12.46～15.54个月），明显长于C组的9个月（95%CI 8.71～9.28个月）；P组中位OS为17个月（95%CI 15.73～18.27个月），明显长于C组的15个月（95%CI 14.37～15.63个月）。P组PFS和OS均明显长于C组（P<0.001）。多因素Cox比例分析结果显示，围术期应用帕瑞昔布明显降低胶质瘤患者术后无进展死亡率（HR=0.25，95%CI 0.15～0.42，P<0.001）和总死亡率（HR=0.38，95%CI 0.25～0.58，P<0.001）。
结论：围术期应用帕瑞昔布可延长胶质瘤手术患者术后生存期，降低术后死亡率。

英文摘要:

      
Objective: To investigate the effect of perioperative use of parecoxib on postoperative survival time in patients with glioma.
Methods: Data of patients undergoing glioma surgery under general anesthesia from January 2019 to May 2023 were retrospectively analyzed. Patients were divided into two groups based on perioperative use of parecoxib: parecoxib group (group P) and control group (group C). General, perioperative, and postoperative survival data, including progression-free survival (PFS) and overall survival (OS), were collected and followed up until May 1, 2024. The patients' baseline data were matched 1∶1 with a propensity score. Kaplan-Meier method was used to compare the survival time of the two groups, and Log-Rank method was used to test the survival difference. Multivariate Cox proportional risk model was used to screen the factors affecting the survival time of patients.
Results: A total of 388 patients were included in this study, including 203 patients in group P and 185 patients in group C. There were 117 patients in each group after propensity score matching. The median PFS in group P was 14 months (95% CI 12.46-15.54 months), which was significantly longer than 9 months (95% CI 8.71-9.28 months) in group C. The median OS in group P was 17 months (95% CI 15.73-18.27 months), which was significantly longer than 15 months (95% CI 14.37-15.63 months) in group C. PFS and OS in group P were significantly longer than those in group C (P < 0.001). Multivariate Cox analysis showed that perioperative use of parexib significantly decreased postoperative progression-free mortality (HR = 0.25, 95% CI 0.15-0.42, P < 0.001) and overall mortality rate (HR = 0.38, 95% CI 0.25-0.58, P < 0.001) in glioma patients.
Conclusion: Perioperative use of parecoxib prolongs postoperative survival time in patients undergoing glioma surgery, reduce postoperative mortality rate.